Edwards (EW) Gains From Balanced Core Growth and New Launches
Edwards (EW) is demonstrating the strong performance of the SAPIEN 3 Ultra valve in the United States, Europe and Rest of World.
Edwards Lifesciences (EW) Q4 Earnings Meet, Margins Dip
Edwards Lifesciences' (EW) Q4 revenues register year-over-year growth on its strong differentiated portfolio of advanced therapies.
Edwards Lifesciences Corporation (EW) Q4 2023 Earnings Call Transcript
Edwards Lifesciences Corporation (EW) Q4 2023 Earnings Call Transcript
Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare ...
Edwards Lifesciences (EW) Q4 Earnings Match Estimates
Edwards Lifesciences (EW) came out with quarterly earnings of $0.64 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.64 per share a year ago.
Edwards Lifesciences beats quarterly estimates on strong heart device sales
Edwards Lifesciences reported fourth-quarter profit on Tuesday that beat Wall Street estimates, helped by strong demand for the company's artificial heart valves and other devices.
Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System
Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.
Stay Ahead of the Game With Edwards Lifesciences (EW) Q4 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top -and-bottom-line estimates for Edwards Lifesciences (EW), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed f...
Strength Seen in Edwards Lifesciences (EW): Can Its 6.2% Jump Turn into More Strength?
Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the ...
Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Edwards Lifesciences is down 3.10% over the last year but I am bullish due to its optimistic outlook and growth initiatives. The company is committed to its shareholders through EPS growth and shar...
ITGR vs. EW: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Edwards Lifesciences (EW). But which of these two stocks offers value investors a be...
Edwards Lifesciences To Spin-Off Critical Care Unit In 2024
On December 7, 2024, Edwards Lifesciences EW Corporation (NYSE: EW, $76.90, Market Capitalization: $46.6 billion) in its annual investor call announced its plans to spin-off its Critical Care unit ...
Edwards Lifesciences (EW) Forwards Growth Strategy and Outlook
Edwards Lifesciences' (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.
Edwards Lifesciences to spin off critical care unit to focus on heart devices
Edwards Lifesciences said on Thursday it would spin off its critical care unit at the end of 2024 to concentrate on its larger heart devices business.
Here's Why You Should Retain Edward Lifesciences (EW) Stock Now
Investors remain optimistic about Edward Lifesciences (EW) due to Surgical's differentiated portfolio and TMTT franchise.
Related Companies